JMP Securities Has Lowered Expectations for Structure Therapeutics (NASDAQ:GPCR) Stock Price

Key Points

• JMP Securities has lowered its price target for Structure Therapeutics (NASDAQ: GPCR) from $89.00 to $87.00, indicating a potential upside of 407.64% based on its previous close.
• In addition to JMP Securities, HC Wainwright and Cantor Fitzgerald have also adjusted their target prices for Structure Therapeutics, with estimates now ranging from $60.00 to $75.00.
• Structure Therapeutics reported a loss of $(0.36) EPS in its latest quarterly earnings, falling short of analysts' expectations of $(0.28) EPS.

Structure Therapeutics (NASDAQ:GPCR - Free Report) had its target price cut by JMP Securities from $89.00 to $87.00 in a report published on Thursday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Several other research analysts have also commented on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, June 23rd. Citigroup started coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. Finally, HC Wainwright dropped their target price on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $75.71.

Structure Therapeutics Trading Up 0.7%

Shares of GPCR traded up $0.11 during trading hours on Thursday, hitting $16.31. The company had a trading volume of 1,139,225 shares, compared to its average volume of 881,394. The company has a market capitalization of $935.22 million, a PE ratio of -15.53 and a beta of -1.89. Structure Therapeutics has a one year low of $13.22 and a one year high of $45.37. The company's fifty day moving average price is $19.78 and its two-hundred day moving average price is $21.81.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). Analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

Several large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $399,000. Good Life Advisors LLC grew its stake in Structure Therapeutics by 15.4% during the 2nd quarter. Good Life Advisors LLC now owns 15,000 shares of the company's stock valued at $311,000 after purchasing an additional 2,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Structure Therapeutics by 18.5% during the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company's stock valued at $1,124,000 after purchasing an additional 8,444 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company's stock valued at $92,000 after purchasing an additional 994 shares during the last quarter. Finally, Quinn Opportunity Partners LLC grew its stake in Structure Therapeutics by 90.9% during the 2nd quarter. Quinn Opportunity Partners LLC now owns 42,000 shares of the company's stock valued at $871,000 after purchasing an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.